BIIB
★★☆☆☆ PassmistralBiogen Inc.
Healthcare · sector percentile 13
세션 움직임
$221.07
거래량 0.80× 평균
35/100 quant · tgt $235.57
ADV$ 186.9M
세션 2026-08-26 · 스냅샷 — 실시간 호가 아님
직전 스캔 대비
2026-08-25 → 2026-08-26
참고용이며 매수/매도 신호가 아닙니다. 스캔 이력과 캐시된 뉴스·공시로 구성됩니다.
스냅샷 시세
세션 2026-08-26 · 스캔 2026-08-26 · 푸시 08-26 16:17 ET · 애프터아워 (오래됨)
시세 상세 보기시세 상세 숨기기
- 종가/스캔가
- $220.77
- 전일 종가
- $220.77
- 푸시 최신가
- $221.07 (오래됨) · 08-26 16:17 ET · 애프터아워
- 세션 시가
- $219.34
- 직전 세션 범위
- $218.69 – $222.00
- 52주 범위
- $199.40 – $222.85
- 세션 거래량
- 646,900
- 평균 거래량 (20일)
- 803,780
- 시가총액
- $32.62B
- PER (TTM)
- 39.21
- Forward PER
- 13.35
- 배당 수익률
- 0.00%
- 1년 목표가 추정
- $235.57
- 다음 실적
- 2026-10-29
Snapshot quote — last daily session bars and scan fundamentals. Not live bid/ask or intraday quotes. 프리/애프터 시세는 유동성이 얇아 정규장과 다를 수 있습니다.
시장 브리핑
선별된 요약입니다 — 매매 신호가 아닙니다. 헤드라인·링크는 제공된 그대로 표시됩니다.
이 종목의 최근 헤드라인이 없습니다.
Price Chart
Daily prices from cache
Loading price history…
AI Analysis
- Bull Thesis — Biogen's momentum score of 9.74 (top decile) and 3M price gain of 14.3% reflect strong investor confidence in its Alzheimer's pipeline, particularly aducanumab's accelerated approval potential and pipeline diversification into neurology.
- Risks — Elevated debt-to-equity ratio (44.3x) and trailing P/E of 39.2x limit financial flexibility, while earnings misses (-84.6% surprise) and EPS decline (-84.8% YoY) raise execution concerns.
- Target Upside — Mean target of $235.57 implies 6.7% upside from $220.77, but valuation remains rich; upside contingent on Alzheimer's drug approvals and pipeline progress.
Score History
20 days of scans. Daily batch adds the next weekday automatically while the API is running.
- DatePriceChgScoreRating
- 2026-08-26$220.77+$2.6535.4Pass
- 2026-08-25$218.12+$1.3433.4Pass
- 2026-08-24$216.78+$2.4335.6Pass
- 2026-08-21$214.35−$7.2135.2Pass
- 2026-08-20$221.56+$9.0135.5Pass
- 2026-08-19$212.55+$3.4035.2Pass
- 2026-08-18$209.15−$0.6835.5Pass
- 2026-08-17$209.83−$0.8235.5Pass
- 2026-08-14$210.65+$0.3333.0Pass
- 2026-08-13$210.32+$6.4332.9Pass
- 2026-08-12$203.89−$3.2434.2Pass
- 2026-08-11$207.13−$0.8135.3Pass
- 2026-08-10$207.94+$1.6635.5Pass
- 2026-08-07$206.28−$0.3535.2Pass
- 2026-08-06$206.63−$1.8235.8Pass
- 2026-08-05$208.45+$6.6336.7Pass
- 2026-08-03$201.82−$1.1335.8Pass
- 2026-08-01$202.95−$1.7535.5Pass
- 2026-07-31$204.70−$3.2334.7Pass
- 2026-07-30$207.93—31.9Pass
Quant Breakdown
Short volume (FINRA)
Off-exchange short sale volume ratio vs recent sessions — not a squeeze forecast.
- Short / total
- 81.4%
- vs 20d (z)
- 3.91
- Short vol
- 207,337
- Status
- ok
Squeeze pressure score
full65/100
- Short leg
- 70
- Call leg
- 75
- Activity
- 0.9
- Call vol share
- 72.1%
- PCR (vol)
- 0.39
- Call OI share
- 73.9%
- ATM IV
- 43.5%
FINRA off-exchange short volume (TRF/ADF consolidated). Not short interest as % of float. Squeeze pressure score (0–100) — free composite of off-exchange short volume and (when available) call-side options activity. Not a probability that a squeeze will occur.
공시 점수 (Disclosure)
캐시된 SEC 공시 기반 News / Insider / Earnings 규칙 다리 — 참고용이며, beat/miss나 매수 신호가 아닙니다.
점수 창에 최근 SEC 공시·실적 일정 입력이 아직 없습니다.
Disclosure event score — rule-based view of recent SEC filings and earnings calendar. Not a prediction that price will move, and not earnings beat/miss.
실적 서프라이즈 (퀀트 맥락)
최근 퀀트 스캔에 캐시된 Yahoo/공개 펀더멘털 수치입니다 — 공시 이벤트 점수에 합산되지 않으며 매수 신호가 아닙니다. 최신 발표보다 늦을 수 있습니다.
최근 보고 서프라이즈 -0.8%
Filings & events
Recent SEC disclosures and earnings dates — context only, not a trade signal.
- Next earnings
- 2026-10-29yahoo_calendar
- Last earnings
- —
- SEC ↗42026-08-05
PRIMARY DOCUMENT
- SEC ↗10-Q2026-07-29
10-Q
- SEC ↗8-K2026-07-29
8-K
- SEC ↗8-K2026-07-01
8-K
- SEC ↗42026-06-11
PRIMARY DOCUMENT
- SEC ↗42026-06-11
PRIMARY DOCUMENT
- SEC ↗42026-06-11
PRIMARY DOCUMENT
- SEC ↗42026-06-11
PRIMARY DOCUMENT
- SEC ↗42026-06-11
PRIMARY DOCUMENT
- SEC ↗42026-06-11
PRIMARY DOCUMENT
SEC filings as reported; earnings dates may come from Yahoo calendar. Context only — not investment advice and not a prediction that price will move on a filing or event.